Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medical Imaging
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 1573-4056
  • E-ISSN: 1875-6603
file format pdf download PDF
side by side viewer icon HTML

Abstract

Objective

This study aimed to assess the response of combretastatin-A4-phosphate (CA4P) in rabbit VX2 liver tumors using intravoxel incoherent motion diffusion-weighted MRI (IVIM DW-MRI).

Methods

Forty rabbits with implanted VX2 liver tumors underwent baseline MRI and were then given 10 mg/kg CA4P (n=20) or saline (n=20). After 4 h, 10 rabbits from each group underwent an MRI examination and were then sacrificed. The remaining rabbits underwent MRI after 1, 3, and 7 days and were then sacrificed. Liver samples were processed for H&E and immunohistochemical staining. IVIM parameters () were compared in the treatment and control groups, and the correlations of IVIM parameters with microvascular density (MVD) were determined.

Results

At 4 h, the two treatment groups had significantly different and values (<0.001), and these values were at their minimum in the treatment group. The treatment group had moderate correlations between MVD and at 4 h (=0.676, =0.032) and 7 days (=0.656, =0.039) and with at 4 h (=0.732, =0.016) and 7 days (=0.748, =0.013), but no correlation was reported between MVD and or in the control group (all >0.05).

Conclusion

IVIM DW-MRI is a sensitive imaging technique. It successfully evaluated the effect of CA4P on VX2 liver tumors in rabbits. The and values correlated with MVD at 4 h and 7 days after using CA4P, indicating that these parameters have the potential to be used as indicators of tumor angiogenesis after treatment.

© 2024 The Author(s). Published by Bentham Open.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmir/10.2174/1573405619666230306110835
2023-04-27
2025-01-19

  • From This Site

    /content/journals/cmir/10.2174/1573405619666230306110835
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmir/20/1/CMIM-20-e060323214365.html?itemId=/content/journals/cmir/10.2174/1573405619666230306110835&mimeType=html&fmt=ahah

References

  1. ÖzA. ServerS. Koyuncu SökmenB. NamalE. İnanN. BalcıN.C. Intravoxel incoherent motion of colon cancer liver metastases for the assessment of response to antiangiogenic treatment: Results from a pilot study.Med. Princ. Pract.202029542943510.1159/00050581431914438
     [Google Scholar]
  2. Abou ElkassemA.M. LoS.S. GunnA.J. ShuchB.M. Dewitt-FoyM.E. AbouassalyR. VaidyaS.S. ClarkJ.I. LouieA.V. SivaS. GrosuA.L. SmithA.D. Role of imaging in renal cell carcinoma: A multidisciplinary perspective.Radiographics20214151387140710.1148/rg.202120020234270355
     [Google Scholar]
  3. ChenJ. QianT. ZhangH. WeiC. MengF. YinH. Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model.Magn. Reson. Imaging201634217718210.1016/j.mri.2015.10.01326518059
     [Google Scholar]
  4. QianT. ChenM. GaoF. MengF. GaoX. YinH. Diffusion-weighted magnetic resonance imaging to evaluate microvascular density after transarterial embolization ablation in a rabbit VX2 liver tumor model.Magn. Reson. Imaging20143281052105710.1016/j.mri.2014.05.01124970024
     [Google Scholar]
  5. ShiY. OehJ. HitzA. HedehusM. Eastham-AndersonJ. PealeF.V.Jr HamiltonP. O’BrienT. SampathD. CaranoR.A.D. Monitoring and targeting Anti-VEGF induced hypoxia within the viable tumor by 19 F–MRI and multispectral analysis.Neoplasia2017191195095910.1016/j.neo.2017.07.01028987998
     [Google Scholar]
  6. FeracoP. ScartoniD. PorrettiG. PertileR. DonnerD. PicoriL. AmelioD. Predict treatment response by magnetic resonance diffusion weighted imaging: A preliminary study on 46 meningiomas treated with proton-therapy.Diagnostics2021119168410.3390/diagnostics1109168434574025
     [Google Scholar]
  7. Le BihanD. BretonE. LallemandD. AubinM.L. VignaudJ. Laval-JeantetM. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.Radiology1988168249750510.1148/radiology.168.2.33936713393671
     [Google Scholar]
  8. Le BihanDJ Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: A closer step toward the "holy grail" of tissue characterization?Radiology19982072305307
     [Google Scholar]
  9. LeeH.J. RhaS.Y. ChungY.E. ShimH.S. KimY.J. HurJ. HongY.J. ChoiB.W. Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: Correlation with histological microvessel density.Magn. Reson. Med.20147141554155810.1002/mrm.2481023798038
     [Google Scholar]
  10. DolciamiM. CapuaniS. CelliV. MaiuroA. PernazzaA. PalaiaI. Di DonatoV. SantangeloG. RizzoS.M.R. RicciP. Della RoccaC. CatalanoC. ManganaroL. Intravoxel Incoherent Motion (IVIM) MR Quantification in Locally Advanced Cervical Cancer (LACC): Preliminary study on assessment of tumor aggressiveness and response to neoadjuvant chemotherapy.J. Pers. Med.202212463810.3390/jpm1204063835455755
     [Google Scholar]
  11. JooI. LeeJ.M. HanJ.K. ChoiB.I. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors.Radiology2014272241742610.1148/radiol.1413116524697148
     [Google Scholar]
  12. Xiao-pingY. JingH. Fei-pingL. YinH. QiangL. LanlanW. WeiW. Intravoxel incoherent motion MRI for predicting early response to induction chemotherapy and chemoradiotherapy in patients with nasopharyngeal carcinoma.J. Magn. Reson. Imaging20164351179119010.1002/jmri.2507526540374
     [Google Scholar]
  13. KarayamaM. YoshizawaN. SugiyamaM. MoriK. YasuiH. HozumiH. SuzukiY. FuruhashiK. FujisawaT. EnomotoN. NakamuraY. InuiN. GoshimaS. SudaT. TakeharaY. Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer.Lung Cancer2020143475410.1016/j.lungcan.2020.03.01332203770
     [Google Scholar]
  14. GaronE.B. NeidhartJ.D. GabrailN.Y. de OliveiraM.R. BalkissoonJ. KabbinavarF. A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.OncoTargets Ther.201697275728310.2147/OTT.S10918627942221
     [Google Scholar]
  15. ZweifelM. JaysonG.C. ReedN.S. OsborneR. HassanB. LedermannJ. ShreevesG. PoupardL. LuS.P. BalkissoonJ. ChaplinD.J. RustinG.J.S. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.Ann. Oncol.20112292036204110.1093/annonc/mdq70821273348
     [Google Scholar]
  16. ShiC LiuD XiaoZ Monitoring tumor response to antivascular therapy using non-contrast intravoxel incoherent motion diffusion-weighted MRI.Cancer research201777133491350110.1158/0008‑5472.CAN‑16‑2499
     [Google Scholar]
  17. ChengJ. WangY. ZhangC.F. WangH. WuW.Z. PanF. HongN. DengJ. Chemotherapy response evaluation in a mouse model of gastric cancer using intravoxel incoherent motion diffusion-weighted MRI and histopathology.World J. Gastroenterol.201723111990200110.3748/wjg.v23.i11.199028373765
     [Google Scholar]
  18. LiuY. De KeyzerF. WangY. WangF. FengY. ChenF. YuJ. LiuJ. SongS. SwinnenJ. BormansG. OyenR. HuangG. NiY. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.Int. J. Cancer201814371817182810.1002/ijc.3156729707770
     [Google Scholar]
  19. LiuY. GuanQ. KongX. De KeyzerF. FengY. ChenF. YuJ. LiuJ. SongS. van PeltJ. SwinnenJ. BormansG. OyenR. WangS. HuangG. NiY. LiY. Predicting therapeutic efficacy of vascular disrupting agent CA4P in rats with liver tumors by hepatobiliary contrast agent Mn-DPDP-enhanced MRI.Transl. Oncol.20201319210110.1016/j.tranon.2019.09.01031810003
     [Google Scholar]
  20. ShaoH. NiY. ZhangJ. ChenF. DaiX. FanG. SunZ. XuK. Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.PLoS One2013812e8264910.1371/journal.pone.008264924376560
     [Google Scholar]
  21. ShaoH. NiY. DaiX. ZhangJ. ChenF. FanG. SunZ. LiY. ZhouH. XuK. Diffusion-weighted MR imaging allows monitoring the effect of combretastatin A4 phosphate on rabbit implanted VX2 tumor model: 12-Day dynamic results.Eur. J. Radiol.201281357858310.1016/j.ejrad.2011.03.00921454029
     [Google Scholar]
  22. WeidnerN. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.Breast Cancer Res. Treat.199536216918010.1007/BF006660388534865
     [Google Scholar]
  23. ThoenyHC De KeyzerF VandecaveyeV Effect of vascular targeting agent in rat tumor model: Dynamic contrast-enhanced versus diffusion-weighted MR imaging.Radiology2005237249249910.1148/radiol.2372041638
     [Google Scholar]
  24. Le BihanD. BretonE. LallemandD. GrenierP. CabanisE. Laval-JeantetM. MR imaging of intravoxel incoherent motions: Application to diffusion and perfusion in neurologic disorders.Radiology1986161240140710.1148/radiology.161.2.37639093763909
     [Google Scholar]
  25. LuoJ. ZhouK. ZhangB. LuoN. BianJ. Intravoxel incoherent motion diffusion-weighted imaging for evaluation of the cell density and angiogenesis of cirrhosis-related nodules in an experimental rat model: Comparison and correlation with dynamic contrast-enhanced MRI.J. Magn. Reson. Imaging202051381282310.1002/jmri.2684531245888
     [Google Scholar]
  26. LiY. WangZ. ChenF. QinX. LiC. ZhaoY. YanC. WuY. HaoP. XuY. Intravoxel incoherent motion diffusion-weighted MRI in patients with breast cancer: Correlation with tumor stroma characteristics.Eur. J. Radiol.201912010868610.1016/j.ejrad.2019.10868631586850
     [Google Scholar]
  27. NoijD.P. MartensR.M. MarcusJ.T. de BreeR. LeemansC.R. CastelijnsJ.A. de JongM.C. de GraafP. Intravoxel incoherent motion magnetic resonance imaging in head and neck cancer: A systematic review of the diagnostic and prognostic value.Oral Oncol.201768819110.1016/j.oraloncology.2017.03.01628438298
     [Google Scholar]
  28. LiangC.Y. ChenM.D. ZhaoX.X. YanC.G. MeiY.J. XuY.K. Multiple mathematical models of diffusion-weighted magnetic resonance imaging combined with prognostic factors for assessing the response to neoadjuvant chemotherapy and radiation therapy in locally advanced rectal cancer.Eur. J. Radiol.201911024925510.1016/j.ejrad.2018.12.00530599868
     [Google Scholar]
  29. MürtzP. PennerA.H. PfeifferA.K. SprinkartA. PieperC. KönigR. BlockW. SchildH. WillinekW. KukukG. Intravoxel incoherent motion model–based analysis of diffusion-weighted magnetic resonance imaging with 3 b-values for response assessment in locoregional therapy of hepatocellular carcinoma.OncoTargets Ther.201696425643310.2147/OTT.S11390927799790
     [Google Scholar]
  30. PriseV. HonessD. StratfordM. WilsonJ. TozerG. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.Int. J. Oncol.200221471772610.3892/ijo.21.4.71712239609
     [Google Scholar]
  31. KanthouC. TozerG.M. Microtubule depolymerizing vascular disrupting agents: Novel therapeutic agents for oncology and other pathologies.Int. J. Exp. Pathol.200990328429410.1111/j.1365‑2613.2009.00651.x19563611
     [Google Scholar]
  32. WangH. ConaM.M. ChenF. YuJ. FengY. LiJ. De KeyzerF. MarchalG. NiY. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.Anticancer Drugs2012231122110.1097/CAD.0b013e328349dd6021857503
     [Google Scholar]
  33. Le BihanD. What can we see with IVIM MRI?Neuroimage2019187566710.1016/j.neuroimage.2017.12.06229277647
     [Google Scholar]
  34. YuanY ZengD ZhangY Intravoxel incoherent motion diffusion-weighted imaging assessment of microvascular characteristics in the murine embryonal rhabdomyosarcoma model.Acta radiologica (Stockholm, Sweden : 1987)202061226026610.1177/0284185119855731
     [Google Scholar]
  35. SongX. WangL. RenH. WeiR. RenJ.L. NiuJ. Intravoxel incoherent motion imaging in differentiation borderline from malignant ovarian epithelial tumors: Correlation With histological cell proliferation and vessel characteristics.J. Magn. Reson. Imaging202051392893510.1002/jmri.2688531373117
     [Google Scholar]
  36. MitaM.M. SargsyanL. MitaA.C. SpearM. Vascular-disrupting agents in oncology.Expert Opin. Investig. Drugs201322331732810.1517/13543784.2013.75955723316880
     [Google Scholar]
/content/journals/cmir/10.2174/1573405619666230306110835
Loading
Intravoxel Incoherent Motion Diffusion-weighted MRI Assessing the Effect of the Vascular Disrupting Agent CA4P on VX2 Liver Tumors in Rabbits
Curr. Med. Imaging 20, E060323214365 (2024); https://doi.org/10.2174/1573405619666230306110835
/content/journals/cmir/10.2174/1573405619666230306110835
/content/journals/cmir/10.2174/1573405619666230306110835
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Intravoxel incoherent motion diffusion-weighted magnetic resonance imaging (IVIM-DW-MRI); Liver neoplasms; Microvascular density (MVD); Rabbits; Vascular disrupting agent (VDA); VX2 tumor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test